Sherbrooke Park Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Sherbrooke Park Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,645	Closed	-$920K	–	703
2023 Q3	$920K	Buy	2,645 +1,045	+65%	+$365K	0.29%	122
2023 Q2	$563K	Buy	1,600 +900	+129%	+$303K	0.3%	146
2023 Q1	$221K	Sell	700 -800	-53%	-$240K	0.33%	157
2022 Q4	$433K	Buy	+1,500	New	+$457K	0.32%	139

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sherbrooke Park Advisers's VRTX Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 2,645 shares — an estimated $920K sold.

Sherbrooke Park Advisers first reported a position in VRTX in Q4 2022 and held it in 4 quarters. The position peaked at $920K in Q3 2023. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Sherbrooke Park Advisers reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Sherbrooke Park Advisers sold 2,645 Vertex Pharmaceuticals shares in Q4 2023, an estimated $920K.
Sherbrooke Park Advisers first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Sherbrooke Park Advisers's Vertex Pharmaceuticals position peaked at $920K in Q3 2023.
1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.